drug_type
RELEVANT_DRUG
intervention_type
Drug (monoclonal antibody)
drug_description
A humanized anti-CD20 IgG1 monoclonal antibody that depletes CD20+ B cells, reducing antigen presentation, proinflammatory cytokines, and B-cell activity in the CNS.
nci_thesaurus_concept_id
C66250
nci_thesaurus_definition
A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen, a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel, is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells of B-cell origin; it plays an important role in B-cell functioning.
drug_mesh_term
Ocrelizumab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and depletes them via complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity, thereby reducing antigen presentation, proinflammatory cytokine release, and B-cell activity in the CNS.
drug_name
Ocrelizumab
nct_id_drug_ref
NCT06159712